[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,023,399
  • Shares Outstanding, K 444,956
  • Annual Sales, $ 49,800 K
  • Annual Income, $ -50,340 K
  • EBIT $ -55 M
  • EBITDA $ -52 M
  • 60-Month Beta 1.08
  • Price/Sales 19.48
  • Price/Cash Flow N/A
  • Price/Book 5.55

Options Overview Details

View History
  • Implied Volatility 128.34% (+57.38%)
  • Historical Volatility 57.23%
  • IV Percentile 46%
  • IV Rank 16.38%
  • IV High 421.18% on 02/09/26
  • IV Low 70.95% on 08/21/26
  • Expected Move (DTE 25) 0.09 (4.03%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 102
  • Volume Avg (30-Day) 160
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 29,230
  • Open Int (30-Day) 31,526
  • Expected Range 2.23 to 2.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 2
  • High Estimate $-0.04
  • Low Estimate $-0.07
  • Prior Year $-0.04
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.96 +18.11%
on 08/06/26
2.52 -8.13%
on 08/04/26
+0.03 (+1.09%)
since 07/24/26
3-Month
1.80 +28.61%
on 06/03/26
2.68 -13.62%
on 06/30/26
+0.15 (+7.18%)
since 05/22/26
52-Week
1.03 +124.76%
on 09/04/25
2.68 -13.62%
on 06/30/26
+1.13 (+94.54%)
since 08/22/25

Most Recent Stories

More News
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1 billion...

LXRX : 2.33 (+1.30%)
Lexicon: Q2 Earnings Snapshot

Lexicon: Q2 Earnings Snapshot

LXRX : 2.33 (+1.30%)
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates 

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027  NDA resubmission activities for ZYNQUISTA ® in type 1 diabetes nearing completion Phase 1 clinical...

LXRX : 2.33 (+1.30%)
Lexicon Pharmaceuticals Reports Earnings Today After Somehow Beating Expectations Last Time

Barchart Research What to Expect from LXRX Earnings LXRX Generated August 5, 2026 Current Price $2.45 EPS Estimate $$-0.05 Consensus Rating Moderate Buy Average Move 9.44% Lexicon Pharmaceuticals Reports...

LXRX : 2.33 (+1.30%)
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August...

LXRX : 2.33 (+1.30%)
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc....

LXRX : 2.33 (+1.30%)
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1 diabetes...

LXRX : 2.33 (+1.30%)
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies...

LXRX : 2.33 (+1.30%)
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C....

LXRX : 2.33 (+1.30%)
Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals (NASDAQ:LXRX) executives highlighted progress across late-stage regulatory programs and efforts to bolster the company’s financial position during the company’s first-quarter...

LXRX : 2.33 (+1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

3rd Resistance Point 2.46
2nd Resistance Point 2.39
1st Resistance Point 2.34
Last Price 2.33
1st Support Level 2.22
2nd Support Level 2.15
3rd Support Level 2.10

See More

52-Week High 2.68
Last Price 2.33
Fibonacci 61.8% 2.05
Fibonacci 50% 1.86
Fibonacci 38.2% 1.66
52-Week Low 1.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.